ストックスクリーナーアプリを入手
1.565
8.40%
0.135
Editas Medicine Inc (EDIT) 最新ニュース
Editas Medicine To Present At The 43rd Annual J.P. Morgan Healthcare Conference - Barchart
Editas Medicine to Present at the 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewswire
Editas Medicine CEO to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan
Top 5 CRISPR Companies To Invest In (January 2025) - Securities.io
Short Interest in Editas Medicine, Inc. (NASDAQ:EDIT) Increases By 5.4% - MarketBeat
Why Is Editas Medicine, Inc. (EDIT) Among the Top CRISPR Stocks to Invest In? - Insider Monkey
State Street Corp Cuts Stake in Editas Medicine, Inc. (NASDAQ:EDIT) - MarketBeat
Editas Medicine, Inc. (NASDAQ:EDIT) Receives $7.00 Average PT from Brokerages - MarketBeat
Editas Medicine (STU:8EM) Cyclically Adjusted FCF per Share : €-1.69 (As of Sep. 2024) - GuruFocus.com
Editas Medicine stock plunges to 52-week low of $1.27 - Investing.com
Cambridge company is laying of 180 people, 65% of its workforce - MSN
Editas Medicine's SWOT analysis: gene editing firm pivots strategy amid stock uncertainty - Investing.com
Editas to cut 65% of workforce in strategy shift; shelves lead gene-editing program - MSN
JP Morgan Downgrades Editas Medicine (EDIT) - MSN
EDIT Stock Falls on Decision to End Reni-Cel Studies, Cut Workforce - MSN
EDIT Stock Falls On Decision To End Reni-Cel Studies, Cut Workforce - Barchart
Editas Medicine (NASDAQ:EDIT) Price Target Lowered to $5.00 at Evercore ISI - MarketBeat
JPMorgan Chase & Co. Downgrades Editas Medicine (NASDAQ:EDIT) to Underweight - MarketBeat
Five things: Editas cuts, CVS shares, Moderna's name and the best birthday gift ever - The Business Journals
Brokerages downgrade gene editing company Editas to 'hold', shares slump 23% - MSN
Editas cut to equal weight by Wells Fargo over reni-cel positioning - MSN
Chardan Capital Downgrades Editas Medicine (EDIT) - MSN
Barclays Cuts Editas Medicine (NASDAQ:EDIT) Price Target to $3.00 - MarketBeat
Editas Medicine price target lowered to $8 from $10 at Baird - Yahoo Finance
Editas Medicine to reduce about 65% of its workforce over the next six months - ETHRWorld.com
Editas Medicine Reshapes Future with In Vivo Focus Amid Major Workforce Cuts - GuruFocus.com
Truist cuts Editas Medicine stock to Hold, removes price target By Investing.com - Investing.com Canada
Editas Medicine (NASDAQ:EDIT) Price Target Lowered to $4.00 at Royal Bank of Canada - MarketBeat
Editas Medicine (EDIT) PT Lowered to $5 at Evercore ISI - StreetInsider.com
Cambridge biotech company lays off more than half its employees - NBC Boston
Gene-editing pioneer Editas lays off more than half its employees - The Business Journals
Editas to cut 65% of workforce in strategy shift; shelves lead gene-editing program (NASDAQ:EDIT) - Seeking Alpha
This Toll Brothers Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday - Benzinga
Editas Medicine's (EDIT) "Neutral" Rating Reaffirmed at Chardan Capital - MarketBeat
Editas Medicine (NASDAQ:EDIT) Price Target Cut to $8.00 by Analysts at Robert W. Baird - MarketBeat
Editas to lay off staff after search for sickle cell partner comes up empty - Yahoo Finance
Editas Medicine (NASDAQ:EDIT) Downgraded to Hold Rating by Truist Financial - MarketBeat
Chardan Capital Markets Downgrades Editas Medicine (EDIT) to Neutral - StreetInsider.com
Editas Medicine (NASDAQ:EDIT) Cut to "Hold" at Stifel Nicolaus - MarketBeat
Editas Axes 60% of Staff, Sickle Cell Therapy After Failing to Find Partner - BioSpace
Editas Medicine Realigns Strategy to Focus on In Vivo Gene Editing, Targets Human Proof Of Concept By 2026 - Benzinga
Editas axes two-thirds of its staff, including its CMO - pharmaphorum
Editas Medicine stock plunges to 52-week low at $1.89 By Investing.com - Investing.com Canada
Editas stock downgraded to hold, price target slashed - Investing.com
Editas Medicine's SWOT analysis: gene editing firm's stock faces pivotal phase - Investing.com Nigeria
Editas Medicine, Inc. Announces Management Changes - Marketscreener.com
Editas shifts focus to in vivo CRISPR gene editing - Investing.com India
Editas to reduce about 65% of its workforce over the next six months - 1470 & 100.3 WMBD
Editas Medicine Announces Strategic Transition to in vivo - GlobeNewswire
Editas Medicine Announces Strategic Transition to in vivo Gene Editing Company with Intent to Achieve Human Proof of Concept in Approximately Two Years - The Manila Times
Editas Medicine Pivots Gene Editing Strategy, Cutting 65% of Workforce - MarketWatch
3.44%
2.04%
大文字化:
|
ボリューム (24 時間):